Growth Hormone Peptides: Complete Guide

Growth hormone (GH) peptides are the most widely prescribed category in peptide therapy. They work by stimulating your pituitary gland to produce and release its own growth hormone — a fundamentally different approach from injecting synthetic HGH directly. That distinction matters for safety, legality, and how your body responds over time.

There are eight GH peptides in common clinical use today: CJC-1295, Ipamorelin, Sermorelin, GHRP-2, GHRP-6, MK-677 (ibutamoren), Tesamorelin, and Hexarelin. Each targets the same end goal — more growth hormone — but they get there through different receptors, with different half-lives, side effect profiles, and price tags. If you’re exploring peptides for muscle growth or anti-aging protocols, understanding these differences is the first step toward choosing the right one.

Key Takeaways

GH peptides fall into two main categories: GHRH analogs (CJC-1295, Sermorelin, Tesamorelin) that mimic the body’s natural GH-releasing hormone, and GH secretagogues (Ipamorelin, GHRP-2, GHRP-6, Hexarelin, MK-677) that activate the ghrelin receptor
Combining a GHRH analog with a secretagogue (like CJC-1295 + Ipamorelin) produces amplified GH release — roughly 2-3x more than either alone
Side effect profiles vary widely: Ipamorelin is the cleanest, while GHRP-6 and MK-677 cause significant hunger and water retention
Only two GH peptides have FDA approval: Sermorelin (discontinued commercially) and Tesamorelin (approved for HIV lipodystrophy)

How GH Peptides Work
The Two Mechanisms: GHRH vs. Ghrelin Pathway
CJC-1295
Ipamorelin
Sermorelin
GHRP-2
GHRP-6
MK-677 (Ibutamoren)
Tesamorelin
Hexarelin
Head-to-Head Comparison
Stacking: Why Combinations Work Better
Side Effects and Safety
Cost Comparison
FAQ
Sources

How GH Peptides Work

Your body already makes growth hormone. The pituitary gland releases it in pulses throughout the day — mostly during deep sleep and after exercise. GH peptides amplify this natural process rather than replacing it.

This matters because exogenous HGH (synthetic growth hormone injections) suppresses your pituitary’s own production through negative feedback. Over time, your body makes less on its own. GH peptides do the opposite: they coax the pituitary to produce more, working within the body’s existing feedback loops [1].

The result is pulsatile GH release that more closely mimics youthful physiology. You still get the negative feedback mechanisms that prevent GH from spiking dangerously high — something that can happen with direct HGH injections. For a deeper look at why this distinction matters, see our breakdown of how peptides work.

The Two Mechanisms: GHRH vs. Ghrelin Pathway

GH peptides stimulate growth hormone through one of two receptor systems. Understanding which pathway a peptide targets explains most of its behavior.

GHRH analogs (CJC-1295, Sermorelin, Tesamorelin) bind the GHRH receptor on the pituitary. They mimic the hypothalamus’s natural growth hormone-releasing hormone signal. These peptides amplify existing GH pulses — they work best when the body is already primed for GH release (during sleep, after fasting, post-exercise).

GH secretagogues / ghrelin mimetics (Ipamorelin, GHRP-2, GHRP-6, Hexarelin, MK-677) bind the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by ghrelin. They can initiate new GH pulses, not just amplify existing ones. This also explains why many of them increase appetite — ghrelin is the body’s hunger hormone.

The clinical sweet spot is combining one peptide from each pathway. The CJC-1295 + Ipamorelin stack is the most popular example of this approach — covered in detail in our CJC-1295 + Ipamorelin guide.

CJC-1295

CJC-1295 is a synthetic GHRH analog with 29 amino acids. It comes in two forms: CJC-1295 with DAC (Drug Affinity Complex) and without DAC (sometimes called Modified GRF 1-29).

Mechanism: Binds the GHRH receptor. The DAC version attaches to albumin in the blood, extending its half-life from about 30 minutes (no DAC) to 6-8 days (with DAC) [2].

Clinical data: A 2006 study by Teichman et al. showed that CJC-1295 with DAC produced dose-dependent increases in GH levels of 2-10x baseline and IGF-1 increases of 1.5-3x that persisted for 6-14 days after a single injection [2]. These are meaningful numbers.

Dosing: CJC-1295 no DAC is typically dosed at 100-300 mcg per injection, 1-3 times daily. CJC-1295 with DAC is dosed at 1-2 mg once or twice weekly due to its longer half-life.

Best for: Sustained IGF-1 elevation, body composition improvement, and as the “base” in combination protocols. Most clinicians now prefer the no-DAC version because the DAC version produces a constant GH elevation rather than natural pulsatile release.

Ipamorelin

Ipamorelin is a pentapeptide (five amino acids) and the most selective GH secretagogue available. Raun et al. identified it in 1998 as the first ghrelin-receptor agonist that stimulates GH release without meaningfully affecting cortisol, prolactin, or ACTH [3].

Mechanism: Binds GHS-R1a selectively. Unlike GHRP-2 and GHRP-6, ipamorelin doesn’t trigger significant cortisol or prolactin release even at high doses [3]. This selectivity makes it the cleanest GH secretagogue for clinical use.

Clinical data: In animal studies, ipamorelin released GH with the same potency as GHRP-6 but without the hormonal side effects. Human studies confirm GH increases of 2-5x baseline depending on dose [3].

Dosing: 200-300 mcg per injection, typically 2-3 times daily. Best results come from dosing 30 minutes before meals or at bedtime. See our ipamorelin benefits guide for more on timing and expected outcomes.

Best for: Patients who want GH optimization without appetite changes or hormonal disruption. First-choice secretagogue for most clinicians.

Sermorelin

Sermorelin is a 29-amino-acid GHRH analog that was FDA-approved in 1997 under the brand name Geref for diagnosing and treating GH deficiency in children. It’s the most studied GH peptide with the longest clinical track record.

Mechanism: Direct GHRH receptor agonist. It’s a truncated version of the body’s natural 44-amino-acid GHRH — the first 29 amino acids, which contain the full biological activity.

Clinical data: Multiple clinical trials demonstrated that sermorelin increases GH secretion, improves body composition, and enhances sleep quality. A six-month study showed improvements in lean body mass, skin elasticity, and energy levels in GH-deficient adults [4]. For a full breakdown of outcomes, see sermorelin results.

Dosing: 200-500 mcg daily, typically injected subcutaneously at bedtime to align with natural GH release during sleep. Our sermorelin dosage guide covers protocols in detail.

Side effects are well-documented given its long history — facial flushing, injection-site reactions, and occasional dizziness. Full breakdown at sermorelin side effects.

Best for: Patients who want the most clinically validated option. The commercial brand was discontinued but it remains available through compounding pharmacies.

GHRP-2

GHRP-2 (Growth Hormone Releasing Peptide-2) is one of the earlier synthetic GH secretagogues. It’s more potent than GHRP-6 and ipamorelin at raw GH release, but that potency comes with tradeoffs.

Mechanism: Binds GHS-R1a with high affinity. Also stimulates cortisol and prolactin release — not as much as GHRP-6, but enough to be clinically relevant [5].

Clinical data: GHRP-2 produces GH increases of 5-15x baseline in studies — among the highest of any peptide in this class [5]. It also increases appetite moderately via ghrelin-pathway activation.

Dosing: 100-300 mcg per injection, 2-3 times daily. Some protocols use lower doses (100 mcg) to minimize cortisol effects while preserving GH release.

Best for: Patients who need stronger GH stimulation and don’t mind moderate appetite increase. Less commonly prescribed now that ipamorelin offers a cleaner profile.

GHRP-6

GHRP-6 was one of the first synthetic GH secretagogues developed. It’s potent but comes with the most side effects in this class.

Mechanism: Binds GHS-R1a and strongly activates ghrelin signaling. This produces strong GH release alongside significant increases in hunger, cortisol, and prolactin [6].

Clinical data: GHRP-6 reliably increases GH levels 3-6x baseline. But it also raises cortisol by 15-20% and produces intense hunger within 20 minutes of injection in most people [6]. For patients trying to lose weight — see peptides for weight loss — this is obviously counterproductive.

Dosing: 100-300 mcg per injection, 2-3 times daily on an empty stomach.

Best for: Patients who are underweight or recovering from illness where appetite stimulation is actually beneficial. Otherwise, newer alternatives (ipamorelin, GHRP-2) have largely replaced it.

MK-677 (Ibutamoren)

MK-677 stands apart from the other peptides here because it’s not actually a peptide — it’s a non-peptide GH secretagogue that can be taken orally. This makes it the only option in this category that doesn’t require injection.

Mechanism: Mimics ghrelin at GHS-R1a, the same receptor as GHRP-6 and ipamorelin. Unlike injectable secretagogues, MK-677 has a half-life of approximately 24 hours, providing sustained GH elevation throughout the day [7].

Clinical data: A two-month study in healthy elderly adults showed MK-677 (25 mg daily) increased GH secretion to levels seen in young adults, with IGF-1 increases of approximately 50% [7]. A separate 12-month trial showed sustained IGF-1 elevation without tachyphylaxis. Body weight increased by about 3 kg, mostly lean mass and water.

Dosing: 10-25 mg orally, once daily. Most take it at bedtime because it can cause drowsiness and hunger.

Side effects: Water retention, increased appetite, mild insulin resistance with long-term use, and numbness/tingling in hands (possible carpal tunnel-like symptoms). These are more pronounced than with injectable GH peptides because MK-677 provides constant rather than pulsatile GH stimulation.

Best for: People who refuse injections. Available as an over-the-counter peptide supplement in some markets, though quality varies dramatically. See our peptide supplements guide for what to watch for.

Tesamorelin

Tesamorelin is the only GH peptide currently FDA-approved (brand name Egrifta). It was approved in 2010 specifically for reducing visceral abdominal fat in HIV-positive patients with lipodystrophy.

Mechanism: GHRH analog — a 44-amino-acid synthetic version of the full-length human GHRH. This is the complete molecule, unlike sermorelin which uses only the first 29 residues.

Clinical data: Phase III trials demonstrated a 15-20% reduction in visceral adipose tissue (VAT) over 26 weeks at the approved 2 mg daily dose [8]. This is a meaningful reduction. Tesamorelin also showed improvements in liver fat and markers of non-alcoholic fatty liver disease (NAFLD) in subsequent studies. It’s recently been approved in a new once-weekly formulation (F8).

Dosing: 2 mg subcutaneous injection daily (FDA-approved dose). Off-label protocols sometimes use 1-2 mg.

Cost: Significantly more expensive than other GH peptides — the brand-name product runs $1,000-1,500/month. Compounded versions are cheaper. See our tesamorelin vs. semaglutide comparison for how it stacks up against GLP-1 drugs for fat loss.

Best for: Targeted visceral fat reduction, especially in patients with metabolic syndrome. The strongest clinical evidence base of any GH peptide for fat loss specifically.

Hexarelin

Hexarelin is the most potent GH secretagogue in terms of raw GH release per dose. It was developed in the 1990s and studied primarily in Europe.

Mechanism: Binds GHS-R1a with the highest affinity of any peptide in this class. Also has direct cardiac effects — it binds a cardiac receptor (CD36) that may provide protective effects on heart tissue [9].

Clinical data: Hexarelin produces GH increases of 6-15x baseline in healthy adults — the strongest acute GH response of any secretagogue [9]. However, it also rapidly develops tachyphylaxis (desensitization). Most studies show diminished response within 4-8 weeks of continuous use, which limits its long-term utility.

Dosing: 100-200 mcg per injection, 2-3 times daily. Cycling (8 weeks on, 4 weeks off) is commonly recommended to prevent desensitization.

Side effects: Similar to GHRP-2 — moderate cortisol and prolactin increases. The tachyphylaxis issue is the main drawback. Also raises appetite, though less than GHRP-6.

Best for: Short-term protocols where maximum GH output is desired. The cardiac protective properties are intriguing but not yet proven in clinical trials for that use.

Head-to-Head Comparison

Here’s how the eight GH peptides compare across the factors that matter most:

Mechanism and GH Output:

GHRH analogs (Sermorelin, CJC-1295, Tesamorelin): 2-5x baseline GH. Amplify existing pulses.
Mild secretagogues (Ipamorelin): 2-5x baseline. Clean GH release, minimal side hormones.
Moderate secretagogues (GHRP-2, MK-677): 5-10x baseline. Some cortisol/prolactin increase.
Strong secretagogues (GHRP-6, Hexarelin): 3-15x baseline. Significant hunger, hormonal effects.

Half-Life:

Shortest: Sermorelin (~10-20 min), GHRP-6 (~20 min), Ipamorelin (~2 hours)
Medium: CJC-1295 no DAC (~30 min), GHRP-2 (~30 min), Hexarelin (~60 min)
Long: CJC-1295 with DAC (6-8 days), MK-677 (~24 hours), Tesamorelin (~26-38 min but dosed daily)

Appetite Effects:

No appetite change: Sermorelin, CJC-1295, Tesamorelin
Mild: Ipamorelin, GHRP-2
Strong: GHRP-6, MK-677, Hexarelin

Administration:

Injectable (subcutaneous): All except MK-677
Oral: MK-677 only

FDA Status:

FDA-approved: Tesamorelin (current), Sermorelin (formerly, discontinued brand)
Prescription via compounding: CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin
Not FDA-approved as drug: MK-677

For a broader view of how GH peptides fit into the full peptide space, our types of peptides guide covers all categories.

Stacking: Why Combinations Work Better

The most effective GH peptide protocols combine a GHRH analog with a secretagogue. Here’s why: GHRH analogs amplify existing GH pulses, while secretagogues initiate new ones. Used together, they produce synergistic GH release — studies show roughly 2-3x more GH from the combination than either compound alone [10].

The most prescribed stack is CJC-1295 + Ipamorelin. CJC-1295 provides the sustained GHRH signal, and ipamorelin adds the ghrelin-pathway activation without cortisol or prolactin issues.

Other common stacks include:

Sermorelin + GHRP-2: Older protocol, still used. More appetite stimulation than the CJC/Ipa stack.
Tesamorelin + Ipamorelin: Premium option for visceral fat reduction.
CJC-1295 + GHRP-6: For patients who want appetite stimulation (post-surgery recovery, underweight).

For broader stacking strategies beyond GH peptides, see our best peptide stacks guide.

Side Effects and Safety

All GH peptides share some common side effects related to increased growth hormone levels: water retention, joint stiffness, tingling/numbness in extremities (particularly hands), and transient blood sugar changes. These are typically dose-dependent and resolve with dose adjustment.

Side effects specific to each peptide:

CJC-1295: Facial flushing, injection site reactions. The DAC version can cause prolonged GH elevation that some patients find uncomfortable.
Ipamorelin: Headache, mild nausea. Fewest hormonal side effects of any secretagogue.
Sermorelin: Facial flushing, dizziness, injection site pain. Full side effects here.
GHRP-2: Increased appetite, mild cortisol elevation, water retention.
GHRP-6: Intense hunger, significant cortisol and prolactin increases, water retention.
MK-677: Water retention (often significant), increased appetite, lethargy, potential insulin resistance with long-term use.
Tesamorelin: Injection site reactions, joint pain, peripheral edema. Anti-drug antibodies develop in ~85% of patients but don’t appear to reduce efficacy [8].
Hexarelin: Cortisol and prolactin elevation, appetite increase, desensitization with continued use.

For a broader view of peptide safety, see our peptide side effects guide and are peptides safe?.

Who should avoid GH peptides: Anyone with active cancer or a history of cancer (GH can promote tumor growth), pregnant or breastfeeding women, and individuals with uncontrolled diabetes. Always work with a qualified peptide doctor who can monitor IGF-1 levels.

Cost Comparison

Pricing varies significantly based on source (brand vs. compounded), dose, and protocol duration. These are approximate monthly costs through a peptide therapy clinic using compounded peptides:

Sermorelin: $150-300/month
CJC-1295 (no DAC): $150-250/month
Ipamorelin: $150-250/month
CJC-1295 + Ipamorelin combo: $200-400/month
GHRP-2: $100-200/month
GHRP-6: $100-200/month
MK-677: $50-100/month (oral, no compounding needed)
Tesamorelin (brand Egrifta): $1,000-1,500/month
Tesamorelin (compounded): $300-600/month
Hexarelin: $150-250/month

These are peptide costs only. Add $50-200/month for clinical monitoring (bloodwork, consultations). For a full cost breakdown including insurance considerations, see peptide therapy cost and how much does peptide therapy cost.

Many clinics now offer online peptide therapy with compounded peptides shipped directly, often at lower prices than in-office visits. Check our guide on does insurance cover peptide therapy — the short answer is usually no, except for FDA-approved tesamorelin.

FAQ

What is the best growth hormone peptide for beginners?▼

Ipamorelin is the standard starting point. It has the fewest side effects, no significant impact on cortisol or prolactin, and predictable GH release. Most clinicians start with ipamorelin alone, then add CJC-1295 after 2-4 weeks to create a combination protocol. See our ipamorelin benefits guide for what to expect.

Are growth hormone peptides the same as HGH?▼

No. GH peptides stimulate your pituitary to release its own growth hormone. HGH (synthetic somatropin) is the actual hormone injected directly. Peptides produce pulsatile, physiologic GH release; HGH provides constant supraphysiologic levels. Peptides are generally considered safer for long-term use because they work within the body’s feedback systems. Our sermorelin vs. HGH guide covers this comparison in depth.

How long do growth hormone peptides take to work?▼

Most patients notice improved sleep quality within 1-2 weeks. Body composition changes (fat loss, muscle gain) typically become measurable at 8-12 weeks. Full results are usually seen at 3-6 months of consistent use. Peptide therapy before and after shows real timelines.

Do growth hormone peptides require a prescription?▼

In the US, most GH peptides require a prescription from a licensed provider and must be obtained through a compounding pharmacy. MK-677 is technically not FDA-scheduled but exists in a regulatory grey area. Tesamorelin is FDA-approved and available through standard pharmacies. See our guides on how to get peptides prescribed and are peptides legal.

Can women use growth hormone peptides?▼

Yes. GH peptides work through the same mechanisms regardless of sex. Women typically use slightly lower doses and may see particular benefits for skin quality, hair growth, and body composition. See peptide therapy for women and sermorelin for women for gender-specific protocols.

Sources

Veldhuis JD, et al. “Physiological attributes of healthy young and old men: pulsatile growth hormone secretion.” J Clin Endocrinol Metab. 1991;73(6):1081-1088. PubMed
Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561. PubMed
Walker RF. “Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?” Clin Interv Aging. 2006;1(4):307-308. PubMed
Bowers CY. “Growth hormone-releasing peptide (GHRP).” Cell Mol Life Sci. 1998;54(12):1316-1329. PubMed
Arvat E, et al. “Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.” J Clin Endocrinol Metab. 2001;86(3):1169-1174. PubMed
Chapman IM, et al. “Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects.” J Clin Endocrinol Metab. 1996;81(12):4249-4257. PubMed
Falutz J, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” N Engl J Med. 2007;357(23):2359-2370. PubMed
Ghigo E, et al. “Growth hormone-releasing peptides.” Eur J Endocrinol. 1997;136(5):445-460. PubMed
Pandya N, et al. “Growth hormone releasing peptide-6 requires endogenous hypothalamic growth hormone releasing hormone for maximal growth hormone stimulation.” J Clin Endocrinol Metab. 1998;83(4):1186-1189. PubMed